Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

Moderna (MRNA) to Announce Quarterly Earnings on Friday

📅 Moderna will release Q2 2026 earnings on Friday, July 31st, before the market opens.

💰 Analysts expect a quarterly loss of $2.00 per share and revenue of $103 million.

🚀 Q1 2026 revenue surged 260.2% year-over-year to $389 million, significantly beating the $236.37 million consensus.

📉 Q1 EPS was a loss of $3.40, missing analyst estimates of a $3.02 loss.

📈 Stock opened at $57.02, trading between its 50-day ($58.42) and 200-day ($51.75) moving averages.

💵 Market capitalization is valued at $22.62 billion with a debt-to-equity ratio of only 0.08.

🏦 Institutional ownership is high at 75.33%, led by significant holdings from Brown Brothers Harriman and Zions Bancorporation.

📊 Morgan Stanley raised its price target to $39.00 with an equal weight rating.

🔻 Bank of America maintains an underperform rating with a price objective of $38.00.

🎯 The average analyst target price is $40.00, reflecting a 'Reduce' consensus rating.

Bullish Signals
  • Moderna reported Q1 2026 revenue of $389 million, which was 260.2% higher than the same quarter last year and significantly exceeded analyst estimates.
  • The company maintains a robust balance sheet with a quick ratio of 2.35 and a current ratio of 2.41, indicating strong liquidity.
  • Debt levels are minimal with a debt-to-equity ratio of just 0.08, providing financial flexibility for R&D or strategic initiatives.
  • Morgan Stanley increased its price target from $33.00 to $39.00, signaling confidence in the company's long-term prospects.
  • Royal Bank of Canada raised its price objective to $45.00, suggesting a more bullish outlook than the broader analyst consensus.
Risk Factors
  • Moderna reported a Q1 2026 EPS loss of $3.40, which missed analyst expectations of a smaller loss of $3.02.
  • Bank of America maintains an underperform rating with a price objective of $38.00, which is below the current stock price.
  • Weiss Ratings reaffirmed a sell rating, while Jefferies Financial Group holds a neutral stance, contributing to a mixed analyst sentiment.
  • The average analyst target price of $40.00 implies a potential downside from the recent trading levels if consensus estimates hold.
Full Analysis
Moderna (NASDAQ: MRNA) is scheduled to announce its Q2 2026 earnings results before the market opens on Friday, July 31st, with a conference call set for 8:00 AM ET. Analysts currently anticipate a loss of $2.00 per share and revenue of approximately $103 million for the quarter. The company previously reported Q1 2026 results on May 1st, delivering a significant surprise with revenue of $389 million against consensus estimates of $236.37 million, representing a 260.2% year-over-year increase. Despite the strong top-line growth, the firm posted an earnings per share (EPS) loss of $3.40, missing analyst expectations of a smaller loss of $3.02. Moderna's stock recently opened at $57.02, trading above its 200-day moving average but below its 50-day average. The company maintains a strong balance sheet with a market capitalization of $22.62 billion and minimal debt, though it carries a negative P/E ratio due to recent losses. Institutional ownership stands at 75.33%. Wall Street sentiment remains mixed ahead of the upcoming report. Major brokerages have issued varied outlooks, with Morgan Stanley raising its price target to $39.00 and Royal Bank of Canada increasing its target to $45.00, while Bank of America maintains an underperform rating with a $38.00 target. The average analyst target price is currently set at $40.00.